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Introduction
In 1923, Lucie Frey, a neurologist at the University
of Warsaw, published her landmark study on the
“syndrome du nerf auriculotemporal”. She described
a 25-year-old patient who developed facial sweating
and local facial skin flushing during meals 5 months
after a gunshot trauma to the parotid region. The
syndrome that bears Frey’s name is characterized by
sweating and flushing resulting from gustatory
stimulation, independent of mastication.1 Frey’s
syndrome has become a synonym that is usually used
for gustatory sweating.
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Background: Gustatory sweating, the main symptom of Frey’s syndrome, usually occurs after parotid gland surgery.
Numerous medical and surgical treatments have been proposed to treat this condition, but there are various drawbacks.
Botulinum toxin type A intracutaneous injection is a relatively new treatment modality; its use has never been reported
in Taiwan. Here, we present our preliminary experience with this technique and review the literature.
Methods: Between March 2002 and June 2005, 10 consecutive patients with severe gustatory sweating were managed
with intracutaneous injection of botulinum toxin type A for a total of 16 times. The affected skin was visualized
by Minor’s starch-iodine test and then recorded. The interinjection distance was 1 cm and a mean dose of
46.4 U (at a concentration of 2.5 U/0.1 mL) was used.
Results: In all 10 cases, gustatory sweating improved within 2 days after injection, with no side effects. Patients
in whom the first 13 injections were performed experienced recurrence of gustatory sweating. Mean duration of
effectiveness was 9.3 months; the shortest duration of effectiveness was 2 months and the longest was 28 months.
One patient also had gustatory flushing, but this symptom did not improve even after 3 treatments.
Conclusion: Intracutaneous injection of botulinum toxin type A is a highly reliable, effective, safe, and minimally
invasive treatment for gustatory sweating. Some patients had long-lasting therapeutic results. We recommend it
as a valuable treatment option for severe cases of gustatory sweating. However, in our experience, it had no effect
on facial skin flushing. Therefore, in addition to acetylcholine, there might be other neurotransmitters that are
responsible for skin vasodilatation. [J Chin Med Assoc 2005;68(10):463–467]
Key Words: botulinum toxin type A, flushing, gustatory, hyperhidrosis, sweating
Currently, most cases of Frey’s syndrome occur
after surgery of the parotid gland. Various theories
have been advocated to account for gustatory
sweating occurring after parotidectomy. At the
present time, the most widely accepted explanation
is the aberrant regeneration theory, which was
initially suggested by Ford and Woodhall.2 According
to the theory, Frey’s syndrome is caused by aberrant
regeneration of postganglionic parasympathetic fibers
feeding the parotid gland that are severed during
parotidectomy. These cholinergic parasympathetic
fibers reach the distal end of the sympathetic fibers
innervating the sweat gland and subcutaneous vessels.
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Because postganglionic parasympathetic nerve fibers
and sympathetic nerve fibers share the same mediator,
acetylcholine, once the aberrant regeneration takes
place, the skin will flush and sweat during eating.
Botulinum toxin type A has been reported to block
neurotransmission at the neuromuscular junction and at
cholinergic autonomic nerve terminals.3 In patients with
Frey’s syndrome, the transmission of the neural input to
the sweat gland and subcutaneous vessels is cholinergic,
as previously mentioned. In 1995, Drobik and Laskawi4
reported the first successful management of Frey’s
syndrome with intracutaneous injection of botulinum
toxin type A. In the ensuing years, several reports from
Western countries have confirmed the effectiveness of
this treatment for gustatory sweating.5–13 However,
there are no reports about this treatment in Taiwanese
patients. We, therefore, present our clinical experiences
with botulinum toxin type A intracutaneous injection
for the treatment of Frey’s syndrome in Taiwanese
patients, and review the background and details about
Frey’s syndrome and this particular treatment.
Methods
Between March 2002 and June 2005, we treated 10
consecutive patients, who developed severe gustatory
sweating following parotidectomy, with botulinum
toxin type A. All patients had gustatory sweating that
occurred during every meal, causing annoyance and/
or embarrassment. Criteria for treatment were intense
gustatory sweating and the desire to be treated.
The exact location of the affected area was assessed
and photographed by means of a starch-iodine test in an
air-conditioned room. The affected cheek was painted
with 10% better iodine alcohol solution. After this had
dried, powdered potato starch was applied onto the
iodine-stained skin. The patient was then given a tablet
of vitamin C to chew for 5 minutes. The extent of the
hyperhidrotic area could then be visualized as small
black spots when sweat from the sweat glands reacted
with the iodine (Figure 1A). This black discoloration
allowed us to delineate the involved skin surface.
None of the patients had contraindications to the
use of botulinum toxin type A (BOTOX®; Allergan
Inc, Westport, County Mayo, Ireland). One ampoule
of BOTOX® contains 100 units of botulinum toxin
type A as a freeze-dried powder. Immediately before
injection, the toxin was reconstituted with 4 mL of
sterile saline solution to a final concentration of 2.5
U/0.1 mL. The borders of the involved skin were
marked with a waterproof pen according to the
starch-iodine test, and then the whole area was divided
into squares of about 1 cm2 each. Intracutaneous
injection was performed without local anesthesia
during an office visit. Typically, 0.1 mL BOTOX®
was infused into 1 cm2 of involved skin with a 1 mL
syringe usually used for insulin injection. However,
the shape of involved skin was sometimes irregular,
so some local concentrations of BOTOX® might have
been higher than estimated in order to cover the
entire area of involved skin. All patients were followed-
up with self-assessment and starch-iodine tests in our
department.
Results
The patients’ characteristics are summarized in Table
1. There were 4 male and 6 female patients; mean
Figure 1. Minor’s starch-iodine test in patient 1 demonstrated: (A) profuse gustatory sweating (arrow) before treatment with botulinum
toxin type A intracutaneous injection; (B) small areas of slight gustatory sweating on the cheek (arrows) 6 months after treatment. This
minimal reaction did not reach the symptomatic threshold and the patient had no complaints.
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age was 49 years (range, 32–82 years). All of these
10 patients with severe Frey’s syndrome had gustatory
sweating involving the parotidomasseteric region, with
another area also being involved in 2 patients (Table
1). The area involved for each injection varied from 6
to 55 cm2 (mean, 18.25 ± 11.52 cm2). Except for
patient 8 who had obvious gustatory flushing (Figure
2) simultaneously with gustatory sweating, other
patients had a sense of hyperhidrosis only.
All injection procedures were performed smoothly
during routine office visits. The total dose for 16
injections ranged from 15 to 137.5 U (mean, 46.4 ±
29 U). Except for tolerable pain during injection, no
other adverse effects such as hematoma, allergy or
facial palsy were encountered during the follow-up
period.
For all subjects, immediate positive results
developed within 2 days after injection. They were all
satisfied and symptom-free by self-assessment,
although some patients’ cheeks showed small areas of
mild gustatory sweating from the starch-iodine test
during follow-up (Figure 1B). The follow-up duration
for each injection was longer than 4 months. During
follow-up after the first 13 injections for 8 patients,
hyperhidrosis recurrence was encountered. The
effective duration for these 13 injections ranged from
2 to 28 months (mean, 9.3 ± 8.1 months) (Table 1).
Patients 1 and 8 have had 3 injections so far. Patient
8 had obvious facial flushing and the shortest effective
duration (2 months each time) for botulinum toxin
type A injection. Patients 1, 2 and 7 had very good
response to previous treatments and asked for second
and third injections after their symptoms recurred.
They were followed-up for more than 4 months after
their last injection, with no recurrence of symptoms
as yet.
Figure 2. Obvious gustatory flushing (arrows) in patient 8.
Table 1. Description of 10 patients treated with botulinum toxin type A
Parotid operation Botulinum toxin type A
No. Gender/ Parotid OP Pathology Sweating Symptom onset after Size of treatment Treatment Follow-up since Effective
Age (yr) area parotid OP (mo) area (cm2) dose (U) first treatment (mo) duration (mo)
1 M/78 RS, SP Salivary duct cyst PM 13 20 62.5 36 8
20 50 15
23 57.5 (5)†
2 M/41 LS* Benign tumor PM 14 18 45 33 20
25 62.5 (4)†
3 F/41 LS, SP Mixed tumor PM 111 13 32.5 33 28
4 M/82 RS, TP, Metastatic cancer PM, B, 15 24 60 29 7
RND SM
5 F/44 LS* Benign tumor PM 13 13 32.5 29 7
6 M/37 LS, SP Mixed tumor PM 7 12 30 25 7
7 F/45 LS, TP Adenoid cystic T, PM 15 22 55 23 16
carcinoma 55 137.5 (4)†
8 F/55 RS, SP Chronic follicular PM 7 10 25 23 2
sialoadenitis 12 30 2
12 30 2
9 F/38 LS, SP Sjögren’s syndrome PM 14 6 15 12 3
10 F/32 LS, TP Mixed tumor PM 13 7 17.5 12 4
*Received parotid operation at other hospitals, so surgical procedure unclear; †patient still being followed-up, so actual duration of effectiveness
not yet determined. B = buccal region; LS = left side; OP = operation; PM = parotidomasseteric region; RND = radical neck dissection;
RS = right side; SM = submandibular region; SP = superficial parotidectomy; T = temporal region; TP = total parotidectomy.
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Discussion
Gustatory sweating on the cheek is the main symptom
of Frey’s syndrome. It is a fairly common embarrassment
following parotid gland surgery. The incidence of
severe noticeable gustatory sweating is about 13%.7
Many treatment modalities have been advocated for
symptomatic gustatory sweating after parotidectomy.
These treatments can be classified into surgical or non-
surgical methods. Surgical treatments include: section
of some portion of the efferent arc, such as the
auriculotemporal nerve, the intracranial portion of the
glossopharyngeal nerve, or the so-called tympanic
neurectomy; reoperation and placement of an
interposition barrier; excising small skin areas where
the sweating occurs; destruction of the stellate ganglion
(chemical sympathectomy) and thoracoscopic
sympathectomy.5,10 Non-surgical treatments include:
radiotherapy; local antiperspirant; local topical or
systemic anticholinergics.5,10,14 All of these methods
are technically difficult or inefficient in the long-term,
or have potential side effects that are worse than the
symptoms they are supposed to treat. Therefore,
explanation and reassurance is commonly considered
to be the most adequate treatment for Frey’s syndrome,
but it is often unsatisfactory. Although some new
topical anticholinergics such as glycopyrrolate have
been reported to be effective, they are still unavailable
in Taiwan. Some have used antiperspirants, but the
results were not satisfactory.15 In any case, the effects
of topical agents are temporary, and repeat applications
are inconvenient.
Recently, several studies4–13 have described the
effectiveness of botulinum toxin type A intracutaneous
injection for gustatory sweating. According to the
literature,2–5,7,8 there seems to be an agreement on the
1 cm interinjection distance and an injection dose of
0.1 mL at a concentration of 25 U/mL, so we used
this protocol to treat our patients. Arad-Cohen and
Blitzer11 suggested that patients return 2–4 weeks
after the first injection to receive re-injection over any
persistent area of gustatory sweating. However, based
on our experience, a single course of injection was
enough to produce symptomatic relief, because any
small area of imperfect response would be insufficient
to reach the subjective “symptom threshold”
(Figure 1B).
After BOTOX® injection, symptom relief was
achieved within 2 days in all of our patients. In the
long term, the time interval between botulinum toxin
injection and symptom recurrence is much longer for
gustatory sweating compared to other indications
such as movement disorders or cosmetic use for
reducing facial wrinkles.11 Laskawi et al7 reported a
mean duration of effectiveness of 17.3 months (range,
11–27 months). They proposed 3 probable mechanisms
for this: the long duration of chemical denervation may
partially or completely abolish sweat gland function;
the autonomic nerve fibers, once chemically denervated,
are regenerated feebly or not at all; the conditions for
regenerating axon terminals are compromised by the
special situation present in the parotid region (scar
formation after extended tissue preparation). In
addition, Laccourreye et al6 attributed this prolonged
effectiveness to disuse atrophy of the muscular fibers
that control the contraction of sweat glands, and to
metaplasia with blockage of the resting sweat gland.
These hypotheses could explain the variability in
regeneration time and, therefore, the variability in
intervals between treatments in different patients.
Unfortunately, we had 1 poor responder to this
treatment. The effect for gustatory sweating in patient
8 lasted for only 2 months each time for the 3 times
tried so far. Guntinas-Lichius16 found that the mean
duration of effectiveness was longer in patients who
were treated with higher concentrations of botulinum
toxin type A. However, further investigation is needed
to determine if higher concentrations of botulinum
toxin type A can prolong the treatment effect in
patients with shorter symptom-free durations after
treatment in this study.
Gustatory flushing is one of the components of
Frey’s syndrome, but rarely complained of by our
patients. Although botulinum toxin type A is effective
in controlling sweating, little is known about flushing.
Tugnoli et al17 reported that botulinum toxin also
inhibited gustatory flushing in Frey’s syndrome.
However, Young18 found that flushing persisted after
sweating had been blocked by atropine. This finding
is similar to ours in the treatment of patient 8. Her
gustatory sweating subsided after each botulinum
toxin type A injection, but her gustatory flushing never
improved. These results imply that, in addition to
acetylcholine, there might be other neurotransmitters
that are responsible for skin vasodilatation.19
Before every injection, our patients were concerned
about the safety of this treatment modality. In reality,
over the entire history of botulinum toxin use in
humans, there have been no reports of deaths resulting
from overdose. According to our experience, there
were no adverse effects after this treatment. However,
temporary slight weakness of the upper lip has been
reported in the literature,6,8,11 and the mimic muscle
near the mouth angle should be avoided when
performing injection. If we can avoid overdoses or
incorrect injections into a muscle or diffusion to a
BOTOX® treatment for Frey’s syndrome
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muscle by keeping the cannula strictly intracutaneous,
it is relatively easy to avoid causing facial weakness.
According to our observation and other reports,
the advantages of botulinum toxin type A injection can
be summarized as follows: (1) can be performed
during routine office visits with minimal discomfort;
(2) effectiveness is always achieved within 2 days of
injection; (3) botulinum toxin type A is relatively safe
for injection, adverse effects are rarely encountered,
and if they are, they are only transient; (4) a long-
lasting therapeutic effect is possible; (5) recurrent
gustatory sweating can be treated with re-injection.
It must be said that the cost of botulinum toxin
type A is high and is not covered by national health
insurance in Taiwan. Compared to the long-term use
of topical agents and other surgical treatments,
however, the cost-effectiveness of this treatment
modality seems acceptable. One bottle of botulinum
toxin type A may also be used for 2 to 3 patients to
decrease each patient’s financial burden. A drawback
of the procedure is pain during injection, but the pain
is tolerable and transient if a 1 mL or 0.3 mL insulin
injection syringe is used. In our patients, none refused
injection because of pain. Topical anesthesia ointment
can be applied over the injection site prior to treatment
to reduce the pain in sensitive patients.
In conclusion, intracutaneous injection of botulinum
toxin type A is a highly reliable treatment for gustatory
sweating. It has, at least, a short-term therapeutic effect,
and long-lasting effect is possible in some patients. It is
a safe and minimally invasive procedure, so repeat
treatment is feasible if symptoms recur. We recommend
it as a valuable treatment option for severe gustatory
sweating. However, further investigation is needed to
determine if increased botulinum toxin type A dosage
benefits poor responders. In this study, we found that
facial flushing did not improve after botulinum toxin
type A treatment. Therefore, in addition to acetylcholine,
there might be other neurotransmitters that are
responsible for skin vasodilatation.
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